Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 6/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26811564 | 0.93 | HTR1A (0.35) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL29566446 | 0.93 | ALK (0.37) | ALKHTR6EGFRHTR1ADRD2 | |
| SCHEMBL24310774 | 0.93 | ALK (0.37) | ALKHTR6EGFRHTR1ADRD2 | |
| SCHEMBL26811548 | 0.92 | ALK (0.33) | ALKHTR6EGFRHTR1ADRD2 | |
| SCHEMBL26811591 | 0.92 | HTR6 (0.38) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL29566746 | 0.89 | HTR1A (0.38) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL24310048 | 0.89 | HTR1A (0.38) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL26811552 | 0.89 | SCN9A (0.34) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL29567132 | 0.89 | HTR1A (0.36) | HTR6EGFRHTR1ADRD2DRD4 | |
| SCHEMBL24310080 | 0.89 | HTR1A (0.36) | HTR6EGFRHTR1ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALK 2616/4885HTR6 2653/4885EGFR 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.